Authorization

SoftBank Vision Fund 2 leads $100 million Series C in digital therapeutics company Biofourmis

Biofourmis, which combines AI-based data analytics and biosensors to monitor the progress of medical treatments, has raised funding from one of the world’s most high-profile investors. The digital therapeutics company, which launched in Singapore and is now headquartered in Boston, announced today it closed a $100 million Series C led by SoftBank Vision Fund 2, with participation from returning investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.
The company’s last funding announcement was in May 2019 for a $35 million Series A led by Sequoia India and MassMutual, the venture capital arm of Massachusetts Mutual Life Insurance Company.
Biofourmis’ platform combines AI-based health analytics and wearable sensors to help healthcare providers gauge patient progress and the effectiveness of drugs and other treatments. The company, founded in 2015 by chief executive Kuldeep Singh Rajput and managing director Wendou Niu, said this is the largest funding for a healthtech startup in Southeast Asia to date. In addition to Boston and Singapore, Biofourmis also has offices in Switzerland and India.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2023    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
3031